OXiGENE, Inc. (OXGN)
-NasdaqCM 3.27 
0.04(1.21%) May 24, 3:23PM EDT
| Prev Close: | 3.31 |
|---|
| Open: | 3.28 |
|---|
| Bid: | N/A |
|---|
| Ask: | 9.00 x 200 |
|---|
| 1y Target Est: | 1.20 |
|---|
| Beta: | 2.3 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.25 - 3.31 |
|---|
| 52wk Range: | 3.10 - 11.76 |
|---|
| Volume: | 10,368 |
|---|
| Avg Vol (3m): | 38,042 |
|---|
| Market Cap: | 6.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -4.95 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OXIGENE INC FinancialsEDGAR Online Financials(Fri, May 17)
- OXIGENE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- OXiGENE Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 6)
- OXiGENE Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 6)
- OXIGENE INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Mon, May 6)
- Q1 2013 OXiGENE, Inc. Earnings Release - After Market CloseCCBN(Mon, May 6)
- OXiGENE's Oncology Drugs Have Run Their Courseat Seeking Alpha(Wed, May 1)
- Oxigene files to sell 4.3M shares of common stock for holderstheflyonthewall.com(Wed, Apr 24)
- OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer TrialGlobeNewswire(Wed, Apr 24)
- OXIGENE INC Files SEC form 8-K, Other EventsEDGAR Online(Wed, Apr 24)
- OXiGENE Announces First Quarter 2013 Earnings Conference Call and WebcastGlobeNewswire(Wed, Apr 24)
- OXiGENE Announces $5 Million Private PlacementGlobeNewswire(Thu, Apr 11)
- OXIGENE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, MEDGAR Online(Thu, Apr 11)
- MARKET PULSE- Health Management, Oxigene, Taylor Morrison, Titan Machineryat Reuters(Wed, Apr 10)
- OXIGENE INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Apr 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 152.89 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company primarily focuses on the development of vascular disrupting agents that disable and destroy abnormal blood vessels, which provi...
View More